Clinical Trial

Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML

Study acronym: VINCENT
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II clinical trial evaluates the efficacy and tolerability of the non-intensive treatment with venetoclax and the hypomethylating agent azacitidine as compared to the standard of care chemotherapy plus gemtuzumab ozogamicin in newly diagnosed NPM1 mutated AML patients fit for intensive chemotherapy.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-06-06; most recent amendment 2024-11-27.
Status change: Not Yet Recruiting → Recruiting 2024-11-27
Trial Details
NCT Number NCT05904106
Lead Sponsor Technische Universität Dresden
Collaborators: University Hospital Heidelberg, AbbVie
Conditions Acute Myeloid Leukemia
Enrollment 146 participants
Start Date 2024-04-07
Primary Completion 2028-09 (estimated)
Study Completion 2028-09 (estimated)
Updated on ClinicalTrials.gov 2024-12-02